Taguchi Keiko, Iihara Hirotoshi, Ishihara Masashi, Komori Yoshifumi, Tanizawa Katsumi, Matsuura Katsuhiko, Itoh Yoshinori
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan.
Anticancer Res. 2009 May;29(5):1721-5.
The significance of repeated treatment with the 5-HT(3) receptor antagonist for prophylaxis of chemotherapy-induced emesis remains to be clarified.
A retrospective analysis was performed to compare the effects of single and repeated treatment with granisetron on anorexia, nausea and vomiting in patients with breast cancer who undertook anthracycline and cyclophosphamide-based cancer chemotherapy.
The control of anorexia was significantly better in the single treatment group than in the repeated treatment group (54% versus 73%; odds ratio (OR), 0.433; 95% confidence intervals (CI), 0.226-0.828; p=0.016), although the rate of complete response to any signs of the gastrointestinal side-effects was not different between the two groups (37% versus 39%; OR, 0.911; CI, 0.489-1.700; p=0.874). However, the incidence of constipation was more frequent in the repeated treatment group (60% versus 37%; OR, 2.586; CI, 1.388-4.818; p=0.003).
Repeated treatment with 5-HT(3) receptor antagonist is not likely to be beneficial to breast cancer patients who undertook anthracycline/cyclophosphamide combination chemotherapy.
5-羟色胺（5-HT）3受体拮抗剂重复治疗对预防化疗引起的呕吐的意义仍有待阐明。
进行回顾性分析，比较格拉司琼单次和重复治疗对接受蒽环类药物和环磷酰胺化疗的乳腺癌患者厌食、恶心和呕吐的影响。
单次治疗组对厌食的控制显著优于重复治疗组（54%对73%；优势比（OR），0.433；95%置信区间（CI），0.226 - 0.828；p = 0.016），尽管两组对任何胃肠道副作用体征的完全缓解率无差异（37%对39%；OR，0.911；CI，0.489 - 1.700；p = 0.874）。然而，重复治疗组便秘的发生率更高（60%对37%；OR，2.586；CI，1.388 - 4.818；p = 0.003）。
5-HT3受体拮抗剂重复治疗对接受蒽环类/环磷酰胺联合化疗的乳腺癌患者可能无益处。
